new commissioner17 Apr 2019 19:00
below is an extract from the latest Biotech Growth Trust fact sheet.not of any great significance but just something of interest
"whilst some investors were concerned Gottlieb' departure chould lead to a more stringent FDA,the appointment of Ned Sharpless as the next commissioner,the current Director of the National Cancer Institute and the co-founder of multiple biotechnology companies,appears to be a positive for the industry.We would expect the constructive regulatory environment for new drug approvals to continue under the current leadership"
we may not agree with the phrase "constructive regulatory environment" so far as mtfb has been concerned but perhaps the new commissioner may be a source of some modest optimism